InvestorsHub Logo
Followers 283
Posts 31200
Boards Moderated 0
Alias Born 07/06/2012

Re: umiak post# 3115

Monday, 11/16/2015 12:43:14 PM

Monday, November 16, 2015 12:43:14 PM

Post# of 6487

I'm actually getting a little excited about the support VG MDT compounds could lend to existing therapies. Getting more tumor control from a successful drug is a value proposition for VG. A new TKI can run $10-$15k per month for treatment.


I like the way you are thinking Umiak! Management is thinking the same :)

Both will be pursued equally but different sources of potential funding. MDT is most likely a collaboration situation, since it works with chemotherapy and off-course grant money. TPT technology will most likely be equity and grant funding.


Fear Uncertainty and Doubt FUD It Ain't Going To Work Here Anymore. Notice the lack of question mark.